Last edition
News about "Arexvy "
US FDA Approves GSK's AREXVY for At-Risk Adults Aged 18 to 49 Years
The US FDA has approved GSK’s RSV vaccine, AREXVY, for adults aged 18–49 who are at increased risk of severe RSV infection, expanding protection to an estimated 21 million at-risk individuals in this age group.
AREXVY | 16/03/2026 | By News Bureau
GSK's RSV Vaccine Arexvy Accepted for Regulatory Review in China for Adults Aged 60 and Above
China’s drug regulator has accepted GSK’s Arexvy for review to prevent RSV-related lower respiratory tract disease in adults 60 and older, with a decision expected in 2027.
Arexvy | 11/02/2026 | By News Bureau | 108
European Commission Expands GSK's RSV Vaccine Arexvy to Adults Aged 18 and Above
GSK’s RSV vaccine Arexvy receives European approval for adults aged 18 plus, marking a major expansion in protection against RSV-related respiratory illness across the region.
Arexvy | 28/01/2026 | By News Bureau | 105
FDA to Review GSK's Application to Expand Arexvy RSV Vaccine Use
The US Food and Drug Administration (FDA) has accepted to review GlaxoSmithKline (GSK)'s application to expand the use of its RSV vaccine, Arexvy, to include adults aged 18–49 who are at increased risk.
Arexvy | 16/07/2025 | By Dineshwori | 259
GSK Announces Positive Data for Arexvy (RSV) Vaccine
Arexvy is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older, including those who are at increased risk due to certain underlying medical conditions.
Arexvy | 10/10/2024 | By Aishwarya | 733
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy